Interleukin (IL)4 and IL13 upregulate monocyte chemoattractant protein1 expression in human bronchial epithelial cells: involvement of p38 mitogenactivated protein kinase, extracellular signalregulated kinase 1/2 and Janus kinase2 but not cJun NH2terminal kinase 1/2 signalling pathways
Microstructural analysis of the anorectic action of peripherally administered 5HT
Testing the carbohydrate-insulin model in mice: The importance of distinguishing primary hyperinsulinemia from insulin resistance and metabolic dysfunction
April 2025 | Volume 24 | Issue 4 | 413 | Copyright April 2025 Published online March 7, 2025 doi:10.36849/JDD.8605 Sophia Daniel BS a,b , Stephanie Waggett BS a,c , Elliott Lyles BS a , Pelin Sagut MD a,d , Parisa Shamaei Zadeh MSPH b , Anthony Marcelletti BHS b , Carol Stegura ME c , Lara Wine Lee MD PhD d a College of Graduate Studies, Medical University of South Carolina, Charleston, SC b College of Medicine, University of Kentucky, Lexington, KY c College of Medicine, Medical University of South Carolina, Charleston, SC d Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston, SC Abstract Glucagon-like peptide-1 (GLP-1) agonists are used to treat type 2 diabetes mellitus (T2DM) and have recently gained approval and popularity for treating obesity and weight loss
Furthermore, p53 knockdown elicited reductions in RhoA and RhoB activity without affecting their protein levels (Fig
